Welcome!

News Feed Item

Easton Pharmaceuticals Finalizing Investment Terms in Private Medical Marijuana Device Company; Moves to Initiate Legal Action Against Libelous Seeking Alpha Article

TORONTO, ON -- (Marketwired) -- 06/25/14 -- Easton Pharmaceuticals Inc. (OTC: EAPH) is near final agreement with a medical marijuana technology company specializing in controlled environment agricultural technologies.

Easton Pharmaceuticals, following due diligence, is moving towards investing in medical marijuana device technology and agricultural product. The investment objective manufactures products designed to ensure that medical marijuana cultivation, bottling, edibility, extract manufacturing and dispensaries maintain the highest quality of food safety standards for antimicrobial and bacteria free facilities. Easton's management believes this great investment opportunity will meet strong industry demand and generate positive revenues which will be highlighted in greater detail following a closing agreement. This investment coincides with the company's over-the-counter delivery technology products including Viorra, a non-invasive topical treatment intended to assist women suffering from a range of Female Sexual Arousal Disorders (FSAD).

Easton, in addition to Viorra, maintains a minority ownership in the early stage cancer drug Xilive which is near finalizing on a deal to have this position vastly increased due to positive responses from patent attorneys. Added to these products and initiatives is a 50% ownership in the early stage drug for the treatment of female sexual arousal disorder. The company's medical marijuana initiatives alongside Viorra are deemed to be the best short term options as excellent potential revenue producers. Easton still maintains discussions with third party partners to open a medical marijuana dispensary(s) in certain counties and jurisdictions within the State of Michigan.

An update to Easton's medical marijuana grower's license initiative within the country of Canada is anticipated to be the company's upcoming announcement.

In other developments, Easton Pharmaceuticals is moving towards taking action against libelous statements made by multiple online sources, in particular Seeking Alpha. The article published March 18, 2014 was written by a Matt Finston who made inaccurate and libelous statements attacking Easton's trading stock. Easton is now taking action against Finston after the company's progress on its medical marijuana initiatives and its wholehearted attempt to give Mr. Finston the benefit of the doubt prior to legal action to allow a retraction of certain statements proved fruitless. The article makes several false and misleading statements about Easton, its product line and history as well as allegations that the company was part of a pump and dump scheme a year earlier which are completely false and libelous. Easton Pharmaceuticals has retained counsel to pursue to the fullest extent of the law Mr. Finston and anyone who affiliated with, encouraged or directed his assignment. Mr. Finston's libelous article has damaged the company with not only market cap but with discussions it was having with other third parties.

Easton's management contacted Mr. Finston about misstating that the company tried to sell Viorra in 1998 when, in actuality, the product's acquisition date was 2009. This writer then changed only the date but made no retraction of any type nor any attempted apologies for the grievous mistake. Mr. Finston then alleged that Easton issued restricted shares a year prior for the purpose of planning a pump and dump with Global links. Management has never issued any shares for pump and dump schemes and it should be noted that those shares belonged to a senior consultant by the name of Mr. Neil Mellor, have yet to be and will never be deposited due to a conflict of interest with Mr. Mellor and his company. This was a defamatory statement which was supposed to be retracted once facts, other inaccuracies and judgments were made clear. This has not happened. Mr. Finston also stated the company was unavailable for comment even though no calls were received. Since his article, Easton has made several requests for Mr. Finston to contact and speak with Easton's management and consultants. However, he has refused to respond to all phone call requests, thus contradicting his own statements. The article's release was at or near the company's peak common stock price, which was followed by countless negative and defamatory postings on several web investor portals namely Investorhub, which continue to this day.

Carla Pepe, CEO of Easton Pharmaceuticals, stated: "We are currently exploring all of our legal options for relief. In addition we believe this to be part of a larger orchestrated effort to short Easton Pharmaceuticals stock so individuals can illegally profit from the company's decline. The company is not against the practice of shorting stocks, but is vehemently against anyone posting inaccurate and defamatory statements to achieve their goals. We are in the process of alerting the regulatory bodies about the events and have instructed counsel to take action against Mr. Finston and any others involved. Our company is doing its utmost to grow its business and enter into certain business segments that can ultimately allow the company to be successful and positive revenue generating. We believe we have a tremendous opportunity ahead in the medical cannabis sector coinciding with our other products and businesses. We remain dedicated to executing our business plan and look forward to updating investors on new and potentially significant milestones for the company as the quarter and first half of the year comes to a close later this month."

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company is also endeavoring to enter other potentially lucrative industries such as medical marijuana. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' product "VIORRA" is an over-the-counter, topical daily use product and aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder); the world market for these female conditions is conservatively estimated to be in the billions.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. There are no guarantees or assurances that any proposals, initiatives or negotiations will result in what the company had originally intended. Any investment made into Easton Pharmaceuticals would be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, will discuss how research has demonstrated the value of Machine Learning in delivering next generation analytics to im...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
Unless you don’t use the internet, don’t live in California, or haven’t been paying attention to the recent news… you should be aware that self-driving cars are on their way to becoming a reality. I have seen them – they are real. If you believe in the future reality of self-driving cars, then continue reading on. If you don’t believe in the future possibilities, then I am not sure what to do to convince you other than discuss the very real changes that will roll out with the consumer producti...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
This is not a small hotel event. It is also not a big vendor party where politicians and entertainers are more important than real content. This is Cloud Expo, the world's longest-running conference and exhibition focused on Cloud Computing and all that it entails. If you want serious presentations and valuable insight about Cloud Computing for three straight days, then register now for Cloud Expo.
IoT device adoption is growing at staggering rates, and with it comes opportunity for developers to meet consumer demand for an ever more connected world. Wireless communication is the key part of the encompassing components of any IoT device. Wireless connectivity enhances the device utility at the expense of ease of use and deployment challenges. Since connectivity is fundamental for IoT device development, engineers must understand how to overcome the hurdles inherent in incorporating multipl...